The addition of miRT-126 to myeloid-specific FVIII expression prevents anti-FVIII antibody generation. (inhibitors). Moreover, inhibitors were eradicated in FVIII pre-immune mice through a regulatory T cell-dependent mechanism. In conclusion, targeting FVIII expression to LSECs and myeloid cells by using LVs with cell-specific promoter minimized off-target expression and immune responses. Therefore, at least for some transgenes, expression at the physiologic site of synthesis can enhance efficacy and safety, resulting in long-term correction of genetic diseases such as HA. Keywords:gene therapy, targeted FVIII expression, hemophilia A, inhibitor titers reversion, Tregs Hemophilia A is an X-linked bleeding disease caused by factor VIII (FVIII) deficiency. Targeting FVIII expression in endothelial and myeloid cells, the natural site of its production, by lentiviral vector gene Lannaconitine transfer, Follenzi et al. obtained therapeutic levels of FVIII activity without formation of neutralizing antibodies in hemophilic mice. == Introduction == Hemophilia A (HA) is an X-linked bleeding disorder affecting 1 in 5,00010,000 live male births and is caused by mutations and/or deletion in the coagulation factor VIII (FVIII) gene.1,2,3Currently, there is no definitive cure for HA, and patients are treated with infusions of FVIII concentrate to treat or prevent bleeding, the latter aimed at sustaining FVIII levels at or above 1% of normal as prophylaxis. Therefore, because HA is a monogenic disease, and even modest amounts of FVIII (1%) can ameliorate the bleeding phenotype and improve the quality of life of affected individuals, the potential of gene therapy represents a powerful solution for the permanent treatment of HA.4Recently, hemophilia B (HB) adult patients were successfully treated with the administration of a single dose of adeno-associated virus (AAV)-derived vectors expressing Lannaconitine human factor IX (FIX) in hepatocytes, resulting in long-term FIX activity.5Moreover, hepatocyte-specific FIX expression using AAV reached therapeutic levels in HB dogs even in the presence of neutralizing antibodies to canine FIX.6Similarly, hepatocyte-specific FIX expression by lentiviral vectors (LVs)7,8,9,10with the presence of the hematopoietic-specific microRNA target sequence (mirT) for miR-142-3p11prevented off-target expression in antigen-presenting cells (APCs) with long-term expression and avoidance of immune response. This approach was successfully applied in dogs and is now under clinical development in humans.12Thus, circumventing the immune response to FVIII may also enable a gene therapy approach for HA, warranting effort in additional to that focused on improving hepatocyte-targeted LV-induced FVIII expression.13,14,15 From the gene therapy perspective, there are two major differences between HA and HB: (1) the normal site of synthesis of mouse or human FVIII is not the hepatocytes, and (2) risk for the formation of long-lasting inhibitor formation to FVIII in HA is 5-fold higher (20%30% of patients) compared with those receiving replacement therapy for HB. Notably, in AAV-induced hepatocyte expression Lannaconitine of human FVIII, FVIII inhibitor develops frequently, whereas using a similar approach, no FIX inhibitor is observed in HB mice injected with AAV-human FIX.16Similarly, AAV liver gene therapy induced human FVIII expression in non-human primates (NHPs) resulted in inhibition in almost all animals and again in only 20% of those NHPs injected with AAV-human FIX. Whether these discrepancies are due to the use of non-species-specific and/or ectopic expression is unknown. Recent studies have demonstrated that FVIII is not secreted by hepatocytes but mainly, although not exclusively, by endothelial cells (ECs).17,18,19These cells simultaneously synthesize Lannaconitine and release von Willebrand factor (vWF), which stabilizes and protects FVIII against premature degradation.20,21The liver is known to induce tolerance, rather than immunity, toward antigens presented locally to T cells22,23by specialized resident cells, such as liver sinusoidal ECs (LSECs) and resident liver macrophages, or Kupffer cells (KCs), which express anti-inflammatory mediators (e.g., interleukin 10 [IL-10], transforming growth factor [TGF-]),24,25thereby directing the immune response toward tolerance.26Moreover, LSECs and KCs were reported to produce and secrete FVIII when transplanted in a murine model of HA.17,27Our goal is to test whether expression of human FVIII in its physiologic site of synthesis is feasible without Rabbit polyclonal to TRIM3 increased immunogenicity. To achieve transgene expression only in certain cell types, cell-specific promoters are widely used, such as the endothelial-specific promoter cadherin 5 type 2, also known as vascular endothelial cadherin (VEC),28the myeloid specific CD11b promoter, or ItgaM.29VEC is a transmembrane protein expressed mainly in ECs with a particular role in EC biology controlling intercellular cell junctions.28CD11b is a leukocyte adhesion molecule, expressed mainly in monocytes and macrophages, which mediates myeloid cells binding to ECs and their migration through the vascular wall.30In addition, specific miRTs can be included in the 3 UTR of the transgene sequence to improve the stringency of transgene expression regulation.8,31In our Lannaconitine studies, we use three different miRTs, miRT-122, miRT-126, and miRT-142-3p. miR-122 is a hepatocyte-specific microRNA with an important part in liver development and liver diseases. 32miR-142-3p is definitely a miRNA indicated primarily in hematopoietic cells.11miR-126.